All In Biotech

Drug Trial Radar · NCT05297578

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults 65 Years and Older

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Jun 15, 2022

Primary completion

Feb 15, 2023

Study completion Feb 15, 2023

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.

Conditions

  • Pneumococcal Vaccines

Interventions

  • 24-Valent Pneumococcal Conjugate VaccineBiological

    0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

  • Pneumococcal 20-valent Conjugate VaccineBiological

    0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After VaccinationTime frame: 7 days after vaccination
  2. Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After VaccinationTime frame: 7 days after vaccination
  3. Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After VaccinationTime frame: 1 month after vaccination
  4. Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs)Time frame: 6 months after vaccination

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Accel Research Sites-Birmingham Clinical Research Unit

    Birmingham, Alabama

  • Accel Research Sites - DeLand Clinical Research Unit

    DeLand, Florida

  • CenExel RCA

    Hollywood, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Meridian Clinical Research

    Savannah, Georgia

  • Pivotal Research Solutions

    Stonecrest, Georgia

  • Healthcare Research Network II, LLC

    Flossmoor, Illinois

  • AMR Newton, formerly Heartland Research Associates

    Newton, Kansas

  • AMR Wichita West

    Wichita, Kansas

  • AMR New Orleans

    New Orleans, Louisiana

  • Healthcare Research Network

    Hazelwood, Missouri

  • Meridian Clinical Research

    Omaha, Nebraska

  • Accellacare of Rocky Mount

    Rocky Mount, North Carolina

  • Meridian Clinical Research

    Cincinnati, Ohio

  • Accellacare of Charleston

    Mt. Pleasant, South Carolina

  • Coastal Carolina Research

    North Charleston, South Carolina

  • Clinical Trials of Texas, LLC

    San Antonio, Texas

  • CenExel JBR Clinical Research

    Salt Lake City, Utah

  • Velocity Clinical Research, Salt Lake City

    West Jordan, Utah

  • Charlottesville Medical Research

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.